Dr. Alain Milot received his medical degree from Laval University in 1985. Following his residency in internal medicine, he completed a fellowship in clinical pharmacology at the Clinical Research Institute of Montreal. He holds a master’s degree in pharmacology from the Université de Montréal and is a certified specialist in clinical hypertension from the American Society of Hypertension. He is also a fellow of the Society for Vascular Medicine.
He has been practicing at the Hôpital Saint-François d’Assise of the CHU de Québec since 1996 where he heads the group of vascular medicine. In addition, he is an Associate Professor of Medicine at Laval University and Director of the vascular medicine fellowship program.
He is a regular researcher in the Populations Health and Optimal Health Practices Area at the CHU de Québec Research Center. His main clinical and epidemiological research projects focus on the study of the relationships between adverse psychosocial work factors, cardiovascular risk factors, masked hypertension, cardiovascular diseases and cognitive functions.
Dr. Milot is a former president of the Société québécoise d’hypertension artérielle as well as co-editor-in-chief of the Therapeutic Guide published by this society. He is also a member of the committee that provides annually-updated Hypertension Canada Guidelines.
10, rue de l'Espinay
B3-540
Québec, Québec
Canada G1L 3L5
- Fréchette, AnnieEmployeeHôpital Saint-François d'Assise+1 418-525-4444, extension 53281annie.frechette@crchudequebec.ulaval.ca
10 Rue de l'Espinay
C3-606
Québec, QC
Canada G1L 3L5 - Nadeau, GuylaineEmployeeHôpital Saint-François d'Assise
10, rue de l'Espinay
C3-606
Québec, Québec
Canada G1L 3L52400 Avenue D'Estimauville+1 418-525-4444, extension 53281+1 418-666-7000, extension 10224+1 418-525-4467guylaine.nadeau@chudequebec.caguylaine.nadeau@crchudequebec.ulaval.ca
U3302
Québec, QC
Canada G1E 6W2 - Richard, ElizabethMaster student
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Journal ArticleLancet, 394 (10193), 2019.
Assessment of the healthy worker survivor effect in the relationship between psychosocial work-related factors and hypertension
Journal ArticleOccup Environ Med, 76 (6), 2019.
Psychosocial Stressors at Work and Ambulatory Blood Pressure
Journal ArticleCurr Cardiol Rep, 20 (12), 2018.
Cohort Profile: The PROspective Québec (PROQ) Study on Work and Health
Journal ArticleInt J Epidemiol, 47 (3), 2018.
Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
Journal ArticleCan J Cardiol, 34 (5), 2018.
Le MAPA. Au coeur du diagnostic et du suivi de l'hypertension artérielle
Journal ArticlePerspect Infirm, 14 (3), 2017.
Double Exposure to Adverse Psychosocial Work Factors and High Family Responsibilities as Related to Ambulatory Blood Pressure at Work: A 5-Year Prospective Study in Women With White-Collar Jobs
Journal ArticlePsychosom Med, 79 (5), 2017.
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Journal ArticleN Engl J Med, 376 (1), 2017.
Masked hypertension and effort-reward imbalance at work among 2369 white-collar workers
Journal ArticleJ Hum Hypertens, 31 (10), 2017.
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
Journal ArticleCirculation, 135 (3), 2017.
Active projects
- Coûts des maladies cardiovasculaires et des problèmes de santé mentale attribuables aux contraintes psychosociales au travail : Une étude longitudinale de 22 ans auprès de 9 000 cols blancs., from 2016-07-01 to 2024-03-31
- Prévenir l’hypertension, le diabète de type 2 et les maladies cardiovasculaires en ciblant les stresseurs psychosociaux au travail, les longues heures de travail et les mauvaises habitudes de vie : Des fractions, from 2022-10-01 to 2026-03-31